Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 16/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 16/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 16/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 15/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 14/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 14/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 14/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429455 | 0.80 | PRKAB2 (0.44) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL25331893 | 0.79 | PRKAG1 (0.50) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL17417709 | 0.77 | GPR17 (0.46) | GPR17PRKAG1PRKAA1PRKAB1PRKAA2 | |
| SCHEMBL17417631 | 0.76 | PRKAB2 (0.53) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL17417627 | 0.73 | F7 (0.46) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL17970547 | 0.73 | AKR1C3 (0.41) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL16360964 | 0.73 | F7 (0.42) | GPR17PRKAG1PRKAA1PRKAB1PRKAA2 | |
| SCHEMBL2034897 | 0.72 | GPR84 (0.51) | PRKAG1PRKAA1PRKAB1PRKAA2PRKAB2 | |
| SCHEMBL20354779 | 0.72 | GPR17 (0.34) | GPR17 | |
| SCHEMBL20354778 | 0.71 | GPR17 (0.38) | GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | GPR17 2677/4885PRKAG1 1625/4885PRKAA1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.